药明生物宣布投资6000万美元在美国新建生产基地 | Bilingual News
药明生物宣布投资6000万美元在美国新建生产基地
WuXi Biologics to Invest $60 Million to Establish a Biologics Production Facility in the United States
(*Please scroll down for English news.)
美国马萨诸塞州伍斯特市，中国上海，
2018年6月11日
全球领先的开放式生物技术平台公司药明生物（WuXi Biologics, 2269.HK）今日宣布，公司计划投资6,000万美元（约合3.8亿人民币）在美国马萨诸塞州伍斯特市（隶属波士顿大都会区）新建现代化生物制药临床样品和商业化生产基地，并创造约150个工作岗位。
这是药明生物在全球范围布局的第十一个生产基地（药明生物十一厂），也是药明生物首次在美国新建生产基地，同时也是公司继爱尔兰、新加坡后投资建设的第三个海外生产基地。
签约仪式现场
【前排左起：伍斯特商业发展局（WBDC）总裁兼首席执行官Craig L. Blais先生，药明生物首席技术官、高级副总裁周伟昌博士，马萨诸塞州副州长Karyn Polito女士，伍斯特市市长Joseph M. Petty先生，麻省生命科学中心（MLSC）总裁兼首席执行官Travis McCready先生】
药明生物为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，其使命是加快和转变生物制药发现、开发及生产，造福全球患者。
即将开建的药明生物美国基地将继续采用全球领先的一次性生物反应器，并率先应用“新一代生物制药生产技术”（连续生产工艺）开展商业化生产，致力于成为全球领先的生物制药“未来工厂”。该基地总产能将达到4,500升，包括2个2,000升流加细胞培养反应器与1个500升灌流工艺生物反应器，基地建成后将拥有生物工艺开发实验室，并同时具备临床样品生产和小规模商业化生产的能力。此项目的推进得到了马萨诸塞州政府、伍斯特商业发展局（WBDC）和麻省生命科学中心（MLSC）的大力支持。
“马萨诸塞州拥有技术领先的公司、顶尖的学术机构和充满竞争力的人才，已经形成全球最具活力的生命科学创新生态系统之一。”马萨诸塞州州长查理·贝克（Charlie Baker）先生说，“我们很高兴药明生物选择在马萨诸塞州进行战略布局，更多企业的投资和快速发展将共同构建更加完整的创新生态系统。”
“这几天在伍斯特市与药明生物管理层的会见交流，让我深信他们将对这里的生命科学产业做出巨大贡献。”马萨诸塞州副州长卡琳·波利托（Karyn Polito）女士表示，“我们很高兴为伍斯特市生物医药产业园的发展而努力，我们将继续为各个领域的合作伙伴提供支持。”
“伍斯特市正在打造全新的生物医药产业园区，我们热烈欢迎药明生物成为首家选择入驻于此的企业。”伍斯特市政执政官Edward M. Augustus, Jr.先生表示，“作为全球生物医药市场中地位日益攀升的投资目的地，伍斯特市十分期待新园区的正式开幕，同时帮助药明生物的首个美国生产基地顺利落成。”
“我们很高兴药明生物选择了美国马萨诸塞州，更重要的是选择了伍斯特市。在马萨诸塞州贝克-波利托政府和伍斯特市政府的支持下，我们通过巨大努力最终促成了此项目成功落地。对伍斯特市而言，今天又是一个重要的日子。”伍斯特商业发展局总裁兼首席执行官Craig L. Blais先生表示。
麻省生命科学中心（MLSC）总裁兼首席执行官特拉维斯·麦克瑞迪（Travis McCready）先生表示，“我们很高兴见证药明生物在美国伍斯特市布局生产基地这一重大里程碑。药明生物全球领先的生物制药专业技术和能力将进一步巩固这里的生命科学创新生态系统，帮助马萨诸塞州的生物制药公司更迅速高效地开发创新疗法。我们将继续为此项目的顺利完成而努力。”
“波士顿大都会区是公认的世界生命科学领域的创新聚集地，药明生物的美国新基地在公司国际化战略中具有至关重要的作用，有助于确保公司生产的符合最高质量标准生物药，通过健全强大的供应链网络，造福全球患者。非常感谢美国马萨诸塞州各界人士对我们的大力支持，相信在大家共同的努力下，这个振奋人心的项目将迅速得到推进。”药明生物董事长李革博士表示。
药明生物首席执行官陈智胜博士表示：“我们非常高兴能在美国伍斯特市投建公司在美国的第一个生产基地，公司众多重要合作伙伴距离此基地车程仅2小时。新基地将有助于满足药明生物日益增长的生物制药开发及生产需求，从而更好地帮助当地合作伙伴加速生物药开发进程。药明生物致力于打造全球生物制药领域更宽、更广、更深的生物制药能力和技术平台，赋能当地及全球合作伙伴。”
关于药明生物
药明生物作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。如需更多信息，请访问：www.wuxibiologics.com.cn。
WuXi Biologics to Invest $60 Million to Establish a Biologics Production Facility in the United States
WORCESTER, MA and SHANGHAI
June 11, 2018
- WuXi Biologics’ first overseas site in the United States
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to invest $60 million and hire approximately 150 employees to establish a state-of-the-art biologics clinical and commercial manufacturing facility in Worcester, Massachusetts in the United States. The facility will be WuXi Biologics’ 11th global drug substance manufacturing facility (MFG11).
WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world.
This state-of-the-art “facility of the future” will be built upon the novel approach that WuXi Biologics has pioneered in deploying single-use bioreactors. It is also designed to run continuous bioprocessing, a next-generation manufacturing technology to be implemented in America for the first time. A total of approximately 4,500 L bioreactor capacity will be installed with two 2,000 L traditional fed-batch and one 500 L perfusion-based continuous processing. This facility will handle both clinical and small volume commercial production. An early-stage bioprocess development lab will also be included.
The new manufacturing facility supported by the Government of Massachusetts, the Worcester Business Development Corporation (WBDC) and the Massachusetts Life Sciences Center (MLSC), is the Company’s first overseas site in the United States, as well as the third outside China subsequent to Ireland and Singapore new sites.
“Massachusetts is home to one of the world’s most dynamic life sciences ecosystems, with leading companies, top-tier academic institutions, and a globally-competitive workforce,” said Massachusetts Governor Charlie Baker. “We are enriched when companies grow and invest here and are pleased to welcome WuXi Biologics’ expansion.”
“Having met WuXi Biologics’ leaders during their recent trip to Worcester, I am confident that they will contribute greatly to the city’s life sciences industry,” said Ms. Karyn Polito, Lieutenant Governor of Massachusetts. “I have been pleased to work on the development of Worcester Biomanufacturing Park and our Administration remains committed to supporting our public private partnership.”
“The City of Worcester is thrilled to welcome WuXi Biologics as its first tenant to the new Biomanufacturing Park,” said Worcester City Manager, Edward M. Augustus Jr.. “As a growing destination in the global biomedical market, the city looks forward to officially opening this impressive campus and is eager to host WuXi Biologics in their first US manufacturing facility.”
“We are delighted that WuXi Biologics has chosen the United States, Massachusetts, but most importantly Worcester. We competed very hard for this one and we prevailed. The Baker / Polito Administration and the City of Worcester stepped up to make this possible. Another great day for Worcester,” said Mr. Craig L. Blais, President and CEO of WBDC.
“We are excited to reach this important milestone on developing WuXi Biologics’ first US bio-manufacturing facility and to announce their intention to move to Worcester,” said Mr. Travis McCready, President and CEO of MLSC. “WuXi Biologics brings a global biologics manufacturing expertise that will enhance our life sciences ecosystem and help Massachusetts biopharma companies develop novel therapies quickly and efficiently. We look forward to continuing to work to finalize this project.”
“Metropolitan Boston is acknowledged as a leader in the biopharmaceutical industry. The new site plays a key role in WuXi Biologics’ global bio-manufacturing network to ensure that biologics are manufactured at the highest quality and within a robust supply chain to benefit patients worldwide. We are grateful for all the support local agencies and the talented people here have provided for us. We believe we can quickly push forward this exciting project,” said Dr. Ge Li, Chairman of WuXi Biologics.
Dr. Chris Chen, CEO of WuXi Biologics, added, “The new site will undoubtedly meet WuXi Biologics’ growing need for biologics development and manufacturing in the near future. Many partners of WuXi Biologics are located within two hours of this new site. We are all very excited to initiate our first US site to enable local companies and expedite biologics development in the United States. We are committed to becoming the most comprehensive capability and technology platform in the global biologics industry to enable both local and global partners.”
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
注：本信息不构成药明生物的信息披露或投资建议